Discovery labs maintain ultra-cold storage for biologics and cell therapies
GMP facilities produce vaccines, biologics & temperature-sensitive drugs
Regional hubs with monitored cold rooms & automated inventory systems
Local storage with precise temperature logging & compliance
Last-mile delivery with insulated packaging to hospitals & homes
Our Mission
RNA, protein, and cell-based therapy distribution is limited by access to the "cold chain" - the infrastructure to keep these fragile medicines cold as they travel across the world to the people who need them. This necessity creates barriers for life-saving therapies in resource-limited and geographically-isolated regions. At Cyternity, we're using nature's lessons to change that.
Just edit this element to add your own HTML.
Nature provides remarkable solutions for long-term biological stability under extreme conditions. Our research harnesses the principles of anhydrobiosis to enable room-temperature preservation of living cells.
These organisms can endure complete water loss for extended periods, then rehydrate and resume normal function—capabilities not found in any mammalian cell types.
Spores survive decades of desiccation
Recover from <5% water content
Anhydrobiotic coiling response
Tun state survival for 30+ years
Chironomid larvae tolerate full drying
Successful anhydrobiotic preservation requires protecting multiple cellular structures simultaneously.
Lipid bilayer integrity
Structure & function
Energy production
Genetic integrity
Transcriptome stability
Stem Cells & T-Cells
mRNA & Viral Vector
Antibodies & Enzymes
Platelets & Plasma
Required for long-term cell storage
Extended dry storage preservation
Cyternity's Origins
Cyternity is founded on the seminal scientific research pioneered at Biomatrica, the former world leader in the biopreservation of nucleic acids, proteins, and diagnostic assays. Biomatrica’s technology platform established industry standards for stabilizing sensitive biological materials without refrigeration. After the company’s acquisition by Exact Sciences in 2018, its dry-state stabilization products—along with the advanced research and development portfolio—were divested and returned to the original founders.
This portfolio includes cutting-edge work in dry-state preservation of live bacterial and eukaryotic cells, representing a major leap beyond legacy stabilization methods. Cyternity will apply this foundational science toward new commercial applications in high-growth markets.
To execute this vision, Cyternity has assembled an A-class research, development, and commercial team focused on transforming advanced biopreservation science into globally scalable products - medicines for anywhere and everywhere.